| 臺大學術典藏 |
2020-03-05T05:37:43Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.;Kuo C.-H.;Shin-Joe Yeh;Tsai L.-K.;Liu Y.-B.;Huang C.-F.;Tang S.-C.;Jeng J.-S.; Lin S.-Y.; Kuo C.-H.; SHIN-JOE YEH; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2020-03-02T12:10:28Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y; Kuo C.-H; Yeh S.-J; Tsai L.-K; Liu Y.-B; Huang C.-F; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2020-11-03T11:07:55Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.;Kuo C.-H.;Yeh S.-J.;Tsai L.-K.;Liu Y.-B.;Huang C.-F.;Sung-Chun Tang;Jeng J.-S.; Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2021-07-08T08:19:41Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
SHIN YI LIN; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2021-12-22T03:53:44Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2020-12-30T07:47:45Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; YEN BIN LIU; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 國立成功大學 |
2020-07-14 |
Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
|
Wu;Pei-Ying;Cheng;Ya-Min;Shen;Meng-Ru;Chen;Yi-Chun;Huang;Yu-Fang;Chou;Cheng-Yang |
| 國立成功大學 |
2020-07-14 |
Real-world Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-line or Relapse Therapy (ROBOT): 8-year Experience
|
黃于芳; Huang, Yu-Fang; Wu, Pei-Ying;Cheng, Ya-Min;Shen, Meng-Ru;Chen, Yi-Chun;Chou, Cheng-Yang |
| 國立成功大學 |
2024 |
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
|
Lee;C, -K.;Yoo;C;Hong;J, Y.;Park;S, J.;Kim;J, W.;Tai;D, W.M.;Kim;H;Korphaisarn;K;Tanasanvimon;S;Chen;S, -C.;Kim;J, W.;Kim;I;Kim;M;Choo;J;Oh;S, -B.;Chen;C, -T.;Bae;W, K.;Kim;H;Huh;S, J.;Yen;C, -J.;Park;S;Lee;D, K.;Chan;L, L.L.;Kang;B;Kang;M;Sundar;R;Choi;H, J.;Chan;S, L.;Chon;H, J.;Lee;M, -A. |
| 國家衛生研究院 |
2025-06 |
Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study
|
Yang, TY;Huang, CT;Liu, PY;Lin, YT;Huang, YS;Chang, PH;Tseng, CH;Chang, YT;Lu, PL;Chen, YC |
